VKH
CBIO

Virtu KCG Holdings’s Crescent Biopharma CBIO Stock Holding History

Virtu KCG Holdings’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$569K Buy
+509
New +$420K 0.02% 1027

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Virtu KCG Holdings's CBIO Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Crescent Biopharma (CBIO) in Q2 2017: 509 shares worth $569K. The stake represents 0.02% of the portfolio and ranks #1027 among its holdings.

69 funds tracked by Wall St. Rank hold CBIO as of Q2 2017.

  • Virtu KCG Holdings held 509 shares of Crescent Biopharma worth $569K as of Q2 2017.
  • Crescent Biopharma was a new Virtu KCG Holdings position in Q2 2017.
  • Crescent Biopharma made up 0.02% of Virtu KCG Holdings's portfolio in Q2 2017, its #1027 holding.
  • 69 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.